These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35482721)

  • 1. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.
    Johnson KM; Jiao B; Bender MA; Ramsey SD; Devine B; Basu A
    PLoS One; 2022; 17(4):e0267448. PubMed ID: 35482721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
    Gallagher ME; Chawla A; Brady BL; Badawy SM
    J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.
    Jiao B; Basu A; Ramsey S; Roth J; Bender MA; Quach D; Devine B
    Value Health; 2022 Feb; 25(2):276-287. PubMed ID: 35094801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.
    Snyder AB; Lakshmanan S; Hulihan MM; Paulukonis ST; Zhou M; Horiuchi SS; Abe K; Pope SN; Schieve LA
    MMWR Surveill Summ; 2022 Oct; 71(9):1-18. PubMed ID: 36201430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
    Basu A; Winn AN; Johnson KM; Jiao B; Devine B; Hankins JS; Arnold SD; Bender MA; Ramsey SD
    Ann Intern Med; 2024 Feb; 177(2):155-164. PubMed ID: 38252942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
    Herring WL; Gallagher ME; Shah N; Morse KC; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B
    Pharmacoeconomics; 2024 Jun; 42(6):693-714. PubMed ID: 38684631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle cell disease: current treatment and emerging therapies.
    Neumayr LD; Hoppe CC; Brown C
    Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease.
    Lubeck D; Agodoa I; Bhakta N; Danese M; Pappu K; Howard R; Gleeson M; Halperin M; Lanzkron S
    JAMA Netw Open; 2019 Nov; 2(11):e1915374. PubMed ID: 31730182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.
    Ramsey SD; Bender MA; Li L; Johnson KM; Jiao B; Devine B; Basu A
    PLoS One; 2022; 17(11):e0278137. PubMed ID: 36445914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
    Beillat M; Durand-Zaleski I; Pirenne F; Bénard S; Chillotti L; Galacteros F
    Front Public Health; 2023; 11():1215605. PubMed ID: 37808997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
    Goshua G; Calhoun C; Ito S; James LP; Luviano A; Krishnamurti L; Pandya A
    Ann Intern Med; 2023 Jun; 176(6):779-787. PubMed ID: 37247420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees.
    Mahesri M; Schneeweiss S; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Desai RJ
    Eur J Haematol; 2021 Feb; 106(2):273-280. PubMed ID: 33155319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of Medicaid enrollees with sickle cell disease: A high need, high cost population.
    Grady A; Fiori A; Patel D; Nysenbaum J
    PLoS One; 2021; 16(10):e0257796. PubMed ID: 34705847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
    Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
    J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.